key: cord-0855507-uekhchgp
authors: Nelli, F.; Giannarelli, D.; Fabbri, A.; Silvestri, M.A.; Giron Berrios, J.R.; Virtuoso, A.; Marrucci, E.; Schirripa, M.; Mazzotta, M.; Onorato, A.; Panichi, V.; Topini, G.; Pessina, G.; Natoni, F.; Signorelli, C.; Chilelli, M.G.; Primi, F.; Ruggeri, E.M.
title: Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study.
date: 2022-04-09
journal: Ann Oncol
DOI: 10.1016/j.annonc.2022.04.002
sha: 0693f4c2adb9f21467dce1a48f25aecc79571cce
doc_id: 855507
cord_uid: uekhchgp

nan

The SARS-CoV-2 variants of concern (VOC) widespread and breakthrough infections prompted additional preventive measures in fully-vaccinated immunocompromised recipients, including actively treated cancer patients 1 

dose of an mRNA-based vaccine for this condition based on evidence from immunosuppressed organ transplant recipients 2 . This study aimed to evaluate the safety, immunogenicity, and clinical outcome of two or three doses of BNT162b2 vaccine (tozinameran) in patients with solid malignancies receiving systemic therapies.

The Vax-On-Third is a prospective, observational study that included adult cancer patients on active treatment within the previous six months and who had completed a two-dose schedule of tozinameran 26 to 22 weeks before enrollment. COVID-19 infection at any time was an exclusion criterion. Patients who received booster dosing (Boost-cohort) compared with those who did not (Unboost-cohort) for different reasons (Supplementary Figure S1) . All enrolled patients were tested for IgG antibody titer against receptor binding domain of SARS-CoV-2 Spike protein (RBD-S1) at baseline (timepoint-1) and four weeks after the third dose (timepoint-2). We used the SARS-CoV-2

IgG II Quant immunoassay on the ARCHITECT i2000sr automated platform (Abbott, Sligo, Ireland) with a cut-point ≥50 AU/mL indicating a positive seroconversion response. A threshold ≥4446 AU/ml was selected as a correlate of 50% vaccine efficacy (VE) against symptomatic COVID-19 infection 3 . The incidence of SARS-CoV-2 infections was monitored in both study cohorts by periodic swab testing. Dedicated safety questionnaires were delivered at timepoint-1 and collected at timepoint-2. Propensity score matching (PSM) was performed to reduce potential selection bias between the cohorts. Proper two-sided tests were applied with a significance level J o u r n a l P r e -p r o o f VE rate (Unboost-cohort: 4.4% vs Boost-cohort: 6.3%; P=0.52) did not differ between cohorts at timepoint-1. The third dose of vaccine resulted in an exponential increase in median anti-RBD-S1

IgG titer [15024 AU/mL (95%CI 11598-19447)], which was significantly higher than assessment at timepoint-1 in both Unboost-(P<0.001) and Boost-cohort (P<0.001). Accordingly, seroconversion rate (99.4%, P<0.001) and 50% VE rate (76.9%, P<0.001) improved significantly in the same comparison (P<0.001, Figure 1B and 1C) . 

COVID-19 vaccination and breakthrough infections in patients with cancer

Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer

All authors express their gratitude to the Strategic Directorate of Viterbo Public Health Agency, whose unselfish commitment made the conduct of this research project possible.